Showing results (41-50 of 51) with videos related to

Sort By:
Pageof 6
Archives of Pharmacal Research|August 12, 2020
Setosphapyrone C and D accelerate macrophages cholesterol efflux by promoting LXRα/ABCA1 pathwayTing Li, Jiayu Yin, Yubin Ji, et al.
Nanoscale|August 19, 2025
Tunable bilayer WS<sub>2</sub>-WSe<sub>2</sub> and WS<sub>2</sub>-MoS<sub>2</sub> lateral heterostructures for self-powered photodetectorsYinghao Chen, Baihui Zhang, Shunhui Zhang, et al.
Frontiers in Immunology|November 8, 2023
A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumorsZhiyu Huang, Yanjun Xu, Wei Hong, et al.
Clinical, Cosmetic and Investigational Dermatology|March 20, 2026
Fibronectin-Based Skin Care Regimens for Skin Recovery After Intense Pulsed Light Therapy: A Split-Face StudyHaixia Feng, Lan Ge, Ge Shi, et al.
The Journal of Chemical Physics|August 22, 2024
Controlled growth of asymmetric chiral TeOx for broad-spectrum, high-responsivity and polarization-sensitive photodetectionBaihui Zhang, Zhikang Ao, Fen Zhang, et al.
Nano Letters|June 7, 2024
Self-Rolled-Up WSe<sub>2</sub> One-Dimensional/Two-Dimensional Homojunctions: Enabling High-Performance Self-Powered Polarization-Sensitive PhotodetectorsBaihui Zhang, Zhikang Ao, Xiang Lan, et al.
ACS Nano|October 22, 2024
Controllable Synthesis of WSe<sub>2</sub>-WS<sub>2</sub> Lateral Heterostructures via Atomic SubstitutionShunhui Zhang, Hang Liu, Fen Zhang, et al.
Advances in Therapy|September 14, 2024
Efficacy and Safety of Iparomlimab, an Anti-PD-1 Antibody, in Patients with Advanced Solid Tumors: A Phase 1c StudyJianping Xiong, Weiwei Ouyang, Mengxiang Yang, et al.
Journal of Gynecologic Oncology|April 12, 2024
QL1604 plus paclitaxel-cisplatin/carboplatin in patients with recurrent or metastatic cervical cancer: an open-label, single-arm, phase II trialCheng Fang, Yun Zhou, Yanling Feng, et al.
British Journal of Cancer|June 21, 2024
QL1209 (pertuzumab biosimilar) versus reference pertuzumab plus trastuzumab and docetaxel in neoadjuvant treatment for HER2-positive, ER/PR-negative, early or locally advanced breast cancer: A multicenter, randomized, double-blinded, parallel-controlled, phase III equivalence trialWenjia Zuo, Zhonghua Wang, Jun Qian, et al.
Pageof 6